A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-25 and is reviewed periodically as new material appears.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
=== Humans === The cycling of and excretion of urea by the kidneys is a vital part of mammalian metabolism. Besides its role as carrier of waste nitrogen, urea also plays a role in the countercurrent exchange system of the nephrons, that allows for reabsorption of water and critical ions from the excreted urine. Urea is reabsorbed in the inner medullary collecting ducts of the nephrons, thus raising the osmolarity in the medullary interstitium surrounding the thin descending limb of the loop of Henle, which makes the water reabsorb. By action of the urea transporter 2, some of this reabsorbed urea eventually flows back into the thin descending limb of the tubule, through the collecting ducts, and into the excreted urine. The body uses this mechanism, which is controlled by the antidiuretic hormone, to create hyperosmotic urine — i.e., urine with a higher concentration of dissolved substances than the blood plasma. This mechanism is important to prevent the loss of water, maintain blood pressure, and maintain a suitable concentration of sodium ions in the blood plasma. The equivalent nitrogen content (in grams) of urea (in mmol) can be estimated by the conversion factor 0.028 g/mmol. Furthermore, 1 gram of nitrogen is roughly equivalent to 6.25 grams of protein, and 1 gram of protein is roughly equivalent to 5 grams of muscle tissue. In situations such as muscle wasting, 1 mmol of excessive urea in the urine (as measured by urine volume in litres multiplied by urea concentration in mmol/L) roughly corresponds to a muscle loss of 0.67 grams.
=== New Zealand and Australia === Sales of A1 protein-free milk in Australia and New Zealand boosted significantly following 2007, after the publication of a book, Devil in the Milk by Keith Woodford, about A1 beta-casein and its perceived dangers to health; the book prompted the New Zealand Food Safety Authority to propose again reviewing the science to address consumer concerns that milk containing both the A1 and A2 proteins might be harmful. It asked the European Food Safety Authority (EFSA) to undertake such a review. The EFSA report, released in 2009, found that "a cause and effect relationship is not established between the dietary intake of BCM7 (beta-casomorphin-7), related peptides or their possible protein precursors and non-communicable diseases". The a2 Milk Company launched an infant formula in New Zealand and Australia in September 2013 and an A1 protein-free thickened cream was launched in January 2014 under the a2 and a2 MILK brands. A2 Corporation changed its name to the a2 Milk Company Limited effective April 2014, and at that time had about 8% market share of the milk products market in Australia. In 2014 Lion, a beverage and food company that operates in Australia and New Zealand and is owned by Kirin, relaunched its Pura Milk product with a new label stating: "Naturally contains A2 protein." The a2 Milk Company announced in November 2014 that it had begun the application process for a dual listing on the Australian Securities Exchange in a bid to open its register to Australian investors and boost the liquidity of its shares.
The Library of Congress website (loc.gov) Library of Congress channel on YouTube Search the Library of Congress catalog Library Of Congress Meeting Notices and Rule Changes from The Federal Register RSS Feed Library of Congress photos on Flickr Works by Library of Congress at Project Gutenberg Works by or about Library of Congress at the Internet Archive Library of Congress at FamilySearch Research Wiki for genealogists "Congress, Library of" . Encyclopedia Americana. 1920. Library of Congress documentary and resources on C-SPAN The Library of Congress National Library Service (NLS) Video: "Library of Congress in 1968 – Computer Automation" on YouTube from Computer History Archive Project Library of Congress Web Archives (Search by URL)
The cardiac examination includes inspection, feeling the chest with the hands (palpation) and listening with a stethoscope (auscultation). It involves assessment of signs that may be visible on a person's hands (such as splinter haemorrhages), joints and other areas. A person's pulse is taken, usually at the radial artery near the wrist, in order to assess for the rhythm and strength of the pulse. The blood pressure is taken, using either a manual or automatic sphygmomanometer or using a more invasive measurement from within the artery. Any elevation of the jugular venous pulse is noted. A person's chest is felt for any transmitted vibrations from the heart, and then listened to with a stethoscope.
Sources: en.wikipedia.org
Further fiber typing methods are less formally delineated, and exist on more of a spectrum. They tend to be focused more on metabolic and functional capacities (i.e., oxidative vs. glycolytic, fast vs. slow contraction time). As noted above, fiber typing by ATPase or MHC does not directly measure or dictate these parameters. However, many of the various methods are mechanistically linked, while others are correlated in vivo. For instance, ATPase fiber type is related to contraction speed, because high ATPase activity allows faster crossbridge cycling. While ATPase activity is only one component of contraction speed, Type I fibers are "slow", in part, because they have low speeds of ATPase activity in comparison to Type II fibers. However, measuring contraction speed is not the same as ATPase fiber typing.
As glucokinase is a monomeric enzyme with only a single binding site for glucose the cooperativity cannot be explained in terms of classical models of equilibrium cooperativity, but requires a kinetic explanation, such as a slow-transition model or a "memonical" model that invokes enzyme memory. The kinetic relationship with the other substrate, MgATP, can be described by classical Michaelis-Menten kinetics, with an affinity at about 0.3–0.4 mM, well below a typical intracellular concentration of 2.5 mM. The fact that there is nearly always an excess of ATP available implies that ATP concentration rarely influences glucokinase activity. The maximum specific activity (kcat) of glucokinase when saturated with both substrates is 62/s. The pH optimum of human glucokinase was identified only recently and is surprisingly high, at pH 8.5–8.7. A "minimal mathematical model" has been devised based on the above kinetic information to predict the beta cell glucose phosphorylation rate (BGPR) of normal ("wild type") glucokinase and the known mutations. The BGPR for wild type glucokinase is about 28% at a glucose concentration of 5 mM, indicating that the enzyme is running at 28% of capacity at the usual threshold glucose for triggering insulin release.
MusclePharm owed vendors approximately $1.1 million in outstanding invoices and was short on funds to pay them the money. 2014 MusclePharm acquired BioZone Laboratories, which included its facility in Richmond, California. This acquisition included BioZone's QuSomes, HyperSorb and, EquaSome technologies, as well as various lines of products including the Arnold Schwarzenegger series in 2013. The acquisition was finalized in late 2013. MusclePharm sold Biozone to Valencia, CA-based Flavor Producers for $9.8 million in April 2016. 2013 MusclePharm Corp. announced plans to buy back $5 million of all common stock in December 2013. In 2013 MusclePharm Corporation completed a $12 million registered direct offering of its Series D Convertible Preferred Stock. The Frost Group, LLC, headed by Miami entrepreneur, and billionaire, Phillip Frost, was the lead investor in the offering and elected to increase its previously announced investment in the offering to a total of $2.9 million. 2012 Marina Ventures sought to force MusclePharm's sale of 21 million shares of common stock. Inter-Mountain Capital sued MusclePharm for alleged failure to sell, seeking damages of $4 million. John's Lone Star Distribution alleged in a suit that MusclePharm entered into illegal price discrimination contracts with a Lone Star competitor with the intention of removing Lone Star from the market. NSF International notified the public that a MusclePharm product improperly bore the "NSF Certified for Sport" mark.
Sources: en.wikipedia.org
== See also == Areas annexed by Nazi Germany British Committee for Refugees from Czechoslovakia Flight and expulsion of Germans (1944–1950) Republic of German-Austria Germans in Czechoslovakia (1918–1938) Pursuit of Nazi collaborators Sudetenland Medal
=== 21st century === The 21st century was marked by the expansion of birth control. On June 15, 2000, the residency requirement for foreign women seeking an abortion was abolished, and on December 13, a law was passed that allows emergency contraception ("morning-after pill") to be issued to minors without parental consent. On July 4, 2001, the legal period for abortion was extended from 10 to 12 weeks, and then from 12 to 14 weeks on February 23, 2022. On December 6th, 2006, a report from the High Council for Population and Family, recommended free and anonymous contraception for minors. On March 25, 2013, a law was passed which includes full reimbursement of abortion and free access to medical contraception for minors over 15. On August 25, 2020, free contraception was extended to girls under the age of 15. On December 6, 2013, a law was enacted authorizing the trial of birthing centers.
=== Crystal Anderson-Conner === Crystal Anderson-Conner is played by Natalie West. Crystal is a close friend of Roseanne, having gone to high school with her and Jackie and later working together with them at Wellman Plastics. A mild-mannered, good-hearted woman, Crystal's kindness is often taken advantage of, even by Roseanne at times. Though Crystal is not oblivious to others using her, she seldom asserts herself, fearing she might lose others' favor or be perceived as unladylike. Crystal's most poignant hallmark is her dating troubles. At the beginning of the series, she has been married three times. Both her marriages to Rusty and Travis, were fairly short and ended in divorce. (However, in season 1, episode 5, it is mentioned that she was widowed at 18.) Her third husband Sonny, the father of her son Lonnie, was killed in a bridge construction accident. After, Crystal endures years of bad relationships before gradually kindling a romance with Dan's father Ed, much to Roseanne's surprise and Dan's consternation. When Crystal and Ed become engaged in Season 3, she reveals she is pregnant. Dan is initially unhappy with either development, further straining his already-difficult relationship with his father. Crystal gives birth to Ed Junior, better known as Little Ed; the following year, she gives birth to her daughter, Angela. Crystal made a few appearances in several revival-era episodes in 2018 and 2019. It is unmentioned if she is still married to Ed Conner. However, in The Conners, when Ed, Sr. dies, he was living alone in rather shabby circumstances.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.